Luke Beshar

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Fluorinov Pharmaceuticals, Inc. manufactures pharmaceutical products. The American company was founded by Abdelmalik Slassi.

New York State Society of Certified Public Accountants is a non-profit organization. It provides a membership program for certified public accountants that offers in-person and online networking opportunities, Continuing Professional Education courses and conferences, the CPA Journal, and other publications. The company was foudned in 1897 and is headquartered in New York, NY.

Sancilio Pharmaceuticals Co. engaged in the development and manufacture of pharmaceutical products. Its product platform, advanced lipid technologies, focuses on the treatment of diseases and disorders related to lipids such as sickle cell, short bowel, severe hypertriglyceridemia and non-alcoholic fatty liver. The company was founded by Frederick Sancilio in October 2004 and was headquartered in Riviera Beach, FL.

Sancilio & Co., Inc. operates as specialty pharmaceutical company. It develops and markets based products including those based on the proprietary Advanced Lipid Technologies platform. The company was founded by Frederick D. Sancilio in 2005 and is headquartered in Riviera Beach, FL.

WSR Corp is a private company that owns and operates auto supply stores. The company is based in Glenview, IL.

The Genlyte Group, Inc. designs and manufactures indoor and outdoor lighting products for the incandescent, fluorescent, emergency, high-intensity discharge (HID), down lighting, medical and commercial decorative lighting and niche markets. The company is headquartered in Burlington, MA.

ArTara Subsidiary, Inc. engages in the research and development of specialty diseases therapeutics. Its programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology or gastrointestinal and metabolic disorders. The company was founded by Jesse Shefferman in 2017 and is headquartered in New York, NY.

Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France.